JP2001517709A5 - - Google Patents

Download PDF

Info

Publication number
JP2001517709A5
JP2001517709A5 JP2000513589A JP2000513589A JP2001517709A5 JP 2001517709 A5 JP2001517709 A5 JP 2001517709A5 JP 2000513589 A JP2000513589 A JP 2000513589A JP 2000513589 A JP2000513589 A JP 2000513589A JP 2001517709 A5 JP2001517709 A5 JP 2001517709A5
Authority
JP
Japan
Prior art keywords
cells
composition
mannose
virus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000513589A
Other languages
English (en)
Japanese (ja)
Other versions
JP4669930B2 (ja
JP2001517709A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB1998/001718 external-priority patent/WO1999016455A1/en
Publication of JP2001517709A publication Critical patent/JP2001517709A/ja
Publication of JP2001517709A5 publication Critical patent/JP2001517709A5/ja
Application granted granted Critical
Publication of JP4669930B2 publication Critical patent/JP4669930B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000513589A 1997-09-29 1998-09-29 抗原に対する細胞媒介性免疫応答を誘導するための免疫調節組成物 Expired - Fee Related JP4669930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6059497P 1997-09-29 1997-09-29
US60/060,594 1997-09-29
PCT/IB1998/001718 WO1999016455A1 (en) 1997-09-29 1998-09-29 Mannose receptor bearing cell line and antigen composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010226648A Division JP5192020B2 (ja) 1997-09-29 2010-10-06 抗原に対する細胞障害性t細胞応答を誘導するための医薬品の製造におけるマンノース受容体保有抗原提示細胞の使用方法

Publications (3)

Publication Number Publication Date
JP2001517709A JP2001517709A (ja) 2001-10-09
JP2001517709A5 true JP2001517709A5 (enExample) 2006-01-05
JP4669930B2 JP4669930B2 (ja) 2011-04-13

Family

ID=22030506

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000513589A Expired - Fee Related JP4669930B2 (ja) 1997-09-29 1998-09-29 抗原に対する細胞媒介性免疫応答を誘導するための免疫調節組成物
JP2010226648A Expired - Fee Related JP5192020B2 (ja) 1997-09-29 2010-10-06 抗原に対する細胞障害性t細胞応答を誘導するための医薬品の製造におけるマンノース受容体保有抗原提示細胞の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010226648A Expired - Fee Related JP5192020B2 (ja) 1997-09-29 2010-10-06 抗原に対する細胞障害性t細胞応答を誘導するための医薬品の製造におけるマンノース受容体保有抗原提示細胞の使用方法

Country Status (10)

Country Link
US (1) US8771701B2 (enExample)
EP (1) EP1027063B1 (enExample)
JP (2) JP4669930B2 (enExample)
AT (1) ATE422893T1 (enExample)
AU (1) AU754065B2 (enExample)
CA (1) CA2304952C (enExample)
DE (1) DE69840578D1 (enExample)
DK (1) DK1027063T3 (enExample)
ES (1) ES2322212T3 (enExample)
WO (1) WO1999016455A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8021667B2 (en) * 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
JP5007409B2 (ja) 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション 樹状細胞に対するヒトモノクローナル抗体
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
AU2001263653B2 (en) * 2000-06-06 2006-06-29 Igavax Pty Ltd Vaccine
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
ZA200506202B (en) 2003-01-31 2006-10-25 Celldex Therapeutics Inc Antibody vaccine conjugates and uses therefor
DK2224954T3 (en) 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
AU2012334825B2 (en) * 2011-11-09 2017-08-24 Ascend Biopharmaceuticals Ltd Immunomodulatory conjugates
WO2014012933A1 (en) * 2012-07-16 2014-01-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the generation of non-transformed macrophage cell lines
CA2938819A1 (en) * 2014-02-06 2015-08-13 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Antibody to mucin 4 (muc4) glycopeptide and uses thereof
CN104721795A (zh) * 2015-04-05 2015-06-24 四川双鑫生物科技有限公司 一种治疗百日咳的内服药物及其制备方法
AU2021255132A1 (en) * 2020-04-13 2022-12-08 Exoprother Medical Ltd. Cell-derived vesicles comprising wild-type P53 protein for antiviral therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2279422A2 (fr) 1974-07-22 1976-02-20 Inst Nat Sante Rech Med Forme pharmaceutique a base d'interferon
US4720386A (en) * 1976-11-24 1988-01-19 Mccollester Duncan L Vaccine and method for immunotherapy of neoplastic disease
JPS61112023A (ja) 1984-11-05 1986-05-30 Tanabe Seiyaku Co Ltd がん細胞傷害活性物質の新規製法
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
EP0326111A3 (en) 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
WO1989008711A1 (en) 1988-03-11 1989-09-21 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
JPH01233219A (ja) 1988-03-12 1989-09-19 Nippon Oil & Fats Co Ltd 制癌剤組成物
AU620149B2 (en) 1988-08-18 1992-02-13 Vaxine Pty Ltd Gamma inulin compositions
WO1990005142A1 (en) 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
CA2098849C (en) 1990-12-20 2007-07-10 Ralph R. Weichselbaum Control of gene expression by ionizing radiation
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5432260A (en) * 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
WO1993006858A1 (en) 1991-10-09 1993-04-15 Dana Farber Cancer Institute, Inc. Lung cancer-associated protein
IL104382A0 (en) 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
JP3043888B2 (ja) 1992-02-20 2000-05-22 森永乳業株式会社 グルコマンナン部分加水分解物を有効成分とする大腸ガン予防剤
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US8021667B2 (en) * 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
EP0849275A1 (en) 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
JP5246860B2 (ja) 2008-09-29 2013-07-24 株式会社前川製作所 急速熱処理装置及び急速熱処理装置用ノズル

Similar Documents

Publication Publication Date Title
JP2001517709A5 (enExample)
Cimica et al. Adjuvant formulations for virus-like particle (VLP) based vaccines
EP0584348B1 (en) Genetic vaccine for immunodeficiency viruses
CA2596274A1 (en) Recombinant mva virus, and the use thereof
JP3857305B2 (ja) 慢性ウイルス性肝臓病に対する治療薬として用いる組成物
JP2004536785A5 (enExample)
CA2304952A1 (en) Mannose-receptor bearing cells and antigen conjugate for immunotherapy
JPH0553474B2 (enExample)
CN102210861A (zh) 丙型肝炎病毒多表位肽负荷的树突状细胞治疗性疫苗
CA2349505A1 (en) Nucleic acid constructs for genetic immunization
EP1136077A1 (en) Preparations containing virus-like particles as immunopotentiators administered through the mucosa
Cruz et al. Characterization and downstream processing of HIV-1 core and virus-like-particles produced in serum free medium
JP3000569B2 (ja) B型肝炎ウイルスコア抗原のアミノ酸残基配列
Baric et al. A Sindbis virus variant with a cell-determined latent period
CN113373179A (zh) 表达SARS-CoV-2纤突蛋白(S)或其变异体的重组VSV病毒及其构建和应用
EP0120922A1 (en) ANTI-VIRAL VACCINES CONTAINING LECTIN FOR DOMESTIC ANIMALS AND THEIR PREPARATION PROCESS.
CN112300290B (zh) 一种使用乳头瘤病毒类病毒颗粒递呈抗原的新型冠状病毒多肽疫苗
Green Chemistry and structure of animal virus particles
Ducos et al. Hepatitis B virus (HBV)-specific in vitro antibody production by peripheral blood mononuclear cells (PBMC) after vaccination by recombinant hepatitis B surface antigen (rHBsAg)
JPWO2002062381A1 (ja) バキュロウイルスベクターワクチン
RU2076735C1 (ru) Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения
Tong et al. In vitro and in vivo replication capacity of the precore region defective hepatitis B virus variants
Avanzini et al. Antigen-specific T cell response in infants after recombinant hepatitis B virus vaccination at birth: evaluation of T helper lymphocyte diversity
Mahr et al. Vaccinia recombinants as vaccine vectors
JPH0534949B2 (enExample)